NASDAQ:GWPHGW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GWPH shares have increased by 10.9% and is now trading at $96.33. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.32. The biopharmaceutical company had revenue of $109.10 million for the quarter, compared to analyst estimates of $80.92 million. GW Pharmaceuticals PLC- had a negative return on equity of 16.12% and a negative net margin of 2.90%. The business's revenue for the quarter was up 1528.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS. View GW Pharmaceuticals PLC-'s earnings history.

14 equities research analysts have issued 1-year target prices for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $128.00 to $260.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $193.00 in the next twelve months. This suggests a possible upside of 100.4% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-.

Headlines about GWPH stock have been trending very negative on Friday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutGW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 5,250,000 shares, a drop of 6.9% from the February 13th total of 5,640,000 shares. Based on an average daily volume of 609,800 shares, the days-to-cover ratio is presently 8.6 days. Currently, 17.1% of the shares of the stock are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.

Some companies that are related to GW Pharmaceuticals PLC- include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Beigene (BGNE), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Mylan (MYL), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Intel (INTC) and Zynerba Pharmaceuticals (ZYNE).

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC-'s stock is owned by a variety of institutional and retail investors. Top institutional investors include M&G Investment Management Ltd. (2.62%) and Investors Financial Group LLC (0.02%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View institutional ownership trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd.. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz, and William A Waldegrave. View insider buying and selling activity for GW Pharmaceuticals PLC-.

GWPH stock was purchased by a variety of institutional investors in the last quarter, including Investors Financial Group LLC. View insider buying and selling activity for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $96.33.

GW Pharmaceuticals PLC- has a market capitalization of $2.98 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe. View additional information about GW Pharmaceuticals PLC-.

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]